Empagliflozin vs Ertugliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT01131676 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).
Next expected readout: November 2026 · NCT05057806 (registry estimate)
Reported efficacy
Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% (met)
Result source: NCT01131676
Ertugliflozin · Steglatro
Marketed by Merck & Co. and partners
NCT01986881 · Phase 3 · completed
This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.
Next expected readout: January 2028 · NCT07621380 (registry estimate)
Reported efficacy
Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years); Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) (Baseline and Week 18): Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years (met)
Result source: NCT01986881
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Empagliflozin | Ertugliflozin |
|---|---|---|
| HbA1c, change | -0.7% vs -0.2%−0.5 vs placeboNCT0115960032 other results
| -1.0% vs 0.2%−1.2 vs placeboNCT0195867165 other results
|
| Body weight, change (kg) | -2.1 vs -0.4−1.7 vs placeboNCT0115960018 other results
| -2.3 vs -0.4−1.9 vs placeboNCT0198688143 other results
|
| HbA1c below 7% | 34.6% vs 24.5%+10.1 vs placeboNCT034295433 other results
| 28.2% vs 15.5%+12.7 vs placeboNCT0198688143 other results
|
| Fasting plasma glucose, change | -1.8 vs 0.3−2.1 vs placeboNCT0173478511 other results
| -1.9 vs -0.9−1 vs placeboNCT0198688163 other results
|
| 3-point MACE (% with event) | 10.4% vs 12.1%−1.7 vs placeboNCT011316762 other results
| —Not posted · NCT03717194 |
HbA1c, change
- Empagliflozin
- -0.7% vs -0.2%−0.5 vs placeboNCT01159600
32 other results
- -0.8% vs -0.2% NCT01159600
- -0.8% vs -0.2% NCT01159600
- -0.8% vs -0.2% NCT01159600
- -1.1% vs -0.1% NCT04233801
- -0.7% vs 0.1% NCT02182830
- -2.8% vs -0.2% NCT01159600
- -2.5% vs -0.2% NCT01159600
- -1.1% vs -0.1% NCT04233801
- -0.9% vs -0.3% NCT02489968
- -0.6% vs 0.1% NCT01734785
- -0.9% vs -0.3% NCT02489968
- -0.9% vs 0.2% NCT02453555
- -0.7% vs 0.1% NCT01734785
- -1.4% vs -1.8% NCT01719003
- -2.1% vs -1.8% NCT01719003
- -0.2% vs 0.3% NCT03429543
- -1.4% vs -1.8% NCT01719003
- -1.9% vs -1.8% NCT01719003
- -2.1% vs -1.8% NCT01719003
- -2.0% vs -1.8% NCT01719003
- -0.5% vs 0.3% NCT03429543
- 0.1% vs 0.3% NCT03429543
- -1.1% vs 0.1% NCT02453555
- -1.1% vs -0.0% NCT02453555
- -0.2% vs 0.1% NCT03429543
- -0.6% vs -0.2% NCT01649297
- -0.7% vs -0.2% NCT01649297
- -0.8% vs -0.2% NCT01649297
- -0.7% vs -0.1% NCT04531462
- -0.9% vs 0% NCT02589639
- -1% vs 0% NCT02589639
- -0.7% vs -0.2% NCT01649297
- Ertugliflozin
- -1.0% vs 0.2%−1.2 vs placeboNCT01958671
65 other results
- -0.9% vs -0.0% NCT02033889
- -0.9% vs -0.1% NCT02036515
- -0.4% vs -0.3% NCT01986855
- -0.9% vs -0.2% NCT02630706
- -0.8% vs -0.2% NCT01986881
- -0.8% vs -0.2% NCT01986881
- -0.8% vs -0.6% NCT01986881
- -1.0% vs -0.2% NCT01986881
- -0.8% vs 0.2% NCT01958671
- -0.7% vs -0.0% NCT02033889
- -0.8% vs -0.1% NCT02036515
- -0.3% vs -0.3% NCT01986855
- -1% vs -0.2% NCT02630706
- -0.9% vs -0.6% NCT01986881
- -0.9% vs -0.2% NCT01986881
- -1.7% vs -0.4% NCT02226003
- -1.6% vs -0.4% NCT02226003
- -0.6% vs 0.1% NCT04029480
- -0.6% vs -0.7% NCT01999218
- -1.1% vs -1.1% NCT02099110
- -0.6% vs -0.7% NCT01999218
- -1.0% vs -1.1% NCT02099110
- -1.5% vs -1.1% NCT02099110
- -1.5% vs -1.1% NCT02099110
- -0.7% vs -0.2% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.5% vs -0.1% NCT01986881
- -0.4% vs -0.0% NCT01986881
- -0.2% vs 0.1% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.5% vs -0.1% NCT01986881
- -0.4% vs -0.0% NCT01986881
- -0.2% vs 0.1% NCT01986881
- -0.3% vs -0.1% NCT01986881
- -0.7% vs -0.7% NCT02033889
- -0.3% vs -0.1% NCT01986881
- -1.0% vs -0.7% NCT02033889
- -0.8% vs 0.0% NCT02036515
- -0.4% vs -0.3% NCT01986855
- -0.9% vs -0.6% NCT02033889
- -0.8% vs 0.0% NCT02036515
- -0.3% vs -0.3% NCT01986855
- -0.5% vs 0.3% NCT04029480
- -0.6% vs -0.6% NCT02033889
- -0.2% vs 0.8% NCT04029480
- -0.4% vs 0.3% NCT04029480
- -0.1% vs 0.2% NCT01986881
- -0.3% vs 0.2% NCT01986881
- -0.8% vs -0.1% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.7% vs -0.1% NCT01059825
- -0.6% vs -0.1% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.5% vs -0.0% NCT01059825
- -0.3% vs 0% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.4% vs -0.0% NCT01059825
- -0.2% vs 0% NCT01059825
- -0.7% vs -0.1% NCT01059825
- -0.5% vs -0.0% NCT01059825
- -0.2% vs 0% NCT01059825
- -0.6% vs -0.1% NCT01059825
- -0.4% vs -0.0% NCT01059825
- -0.1% vs 0% NCT01059825
Body weight, change (kg)
- Empagliflozin
- -2.1 vs -0.4−1.7 vs placeboNCT01159600
18 other results
- -2.2 vs -0.4 NCT01159600
- -2.5 vs -0.4 NCT01159600
- -2.4 vs -0.4 NCT01159600
- -0.8 vs -0.0 NCT03429543
- -2.0 vs 0.0 NCT04233801
- -2.2 vs -1.0 NCT02182830
- -1.3 vs -0.4 NCT01159600
- -1.3 vs -0.4 NCT01159600
- -1.3 vs 0.0 NCT04233801
- -2.5 vs -0.3 NCT01734785
- -3.1 vs -0.3 NCT01734785
- 1.3 vs -0.0 NCT03429543
- -2.4 vs -1.3 NCT01719003
- -2.4 vs -1.3 NCT01719003
- -3.8 vs -1.3 NCT01719003
- -3.0 vs -1.3 NCT01719003
- -3.5 vs -1.3 NCT01719003
- -2.8 vs -1.3 NCT01719003
- Ertugliflozin
- -2.3 vs -0.4−1.9 vs placeboNCT01986881
43 other results
- -2.8 vs -0.4 NCT01986881
- -3.2 vs -0.7 NCT01986881
- -3.4 vs -1.0 NCT01986881
- -3.8 vs -1.3 NCT01986881
- -2.0 vs -0.4 NCT01986881
- -2.5 vs -0.4 NCT01986881
- -2.8 vs -0.7 NCT01986881
- -3.0 vs -1.0 NCT01986881
- -3.4 vs -1.3 NCT01986881
- -3.6 vs -1.4 NCT01958671
- -2.9 vs -1.3 NCT02033889
- -3.0 vs -1.3 NCT02036515
- -3.2 vs -1.2 NCT02630706
- -2.1 vs -0.3 NCT01986881
- -3.4 vs 0.1 NCT02033889
- -4.6 vs -1.2 NCT01986881
- -1.9 vs -0.3 NCT01986881
- -3.7 vs -1.2 NCT01986881
- -1.4 vs 0.5 NCT01986855
- -1.2 vs -0.7 NCT01986881
- -2.4 vs -0.5 NCT01986881
- -2.8 vs -0.9 NCT02036515
- -3.6 vs -0.2 NCT02033889
- -3.2 vs -1.4 NCT01958671
- -3.0 vs -1.3 NCT02033889
- -3.4 vs -1.3 NCT02036515
- -1.3 vs 0.5 NCT01986855
- -3.0 vs -1.2 NCT02630706
- -1.8 vs -0.7 NCT01986881
- -2.0 vs -0.5 NCT01986881
- -3.2 vs 0.1 NCT02033889
- -3.5 vs -0.9 NCT02036515
- -3.8 vs -0.2 NCT02033889
- -3.0 vs -0.9 NCT02226003
- -2.9 vs -0.9 NCT02226003
- -7.4 vs -1.0 NCT01986881
- -4.2 vs -1.0 NCT01986881
- -3.7 vs -0.7 NCT02099110
- -3.4 vs 0.9 NCT01999218
- -2.7 vs -0.7 NCT02099110
- -3.0 vs 0.9 NCT01999218
- -2.9 vs -0.7 NCT02099110
- -2.5 vs -0.7 NCT02099110
HbA1c below 7%
- Empagliflozin
- 34.6% vs 24.5%+10.1 vs placeboNCT03429543
3 other results
- 16.7% vs 8.2% NCT04233801
- 30.1% vs 8.2% NCT04233801
- 66.7% vs 24.5% NCT03429543
- Ertugliflozin
- 28.2% vs 15.5%+12.7 vs placeboNCT01986881
43 other results
- 29% vs 17.4% NCT01986881
- 23.8% vs 16.6% NCT01986881
- 22.7% vs 16.9% NCT01986881
- 22.7% vs 18.2% NCT01986881
- 28.4% vs 15.5% NCT01986881
- 28.3% vs 17.4% NCT01986881
- 23.9% vs 16.6% NCT01986881
- 23.1% vs 16.9% NCT01986881
- 35.8% vs 13.1% NCT01958671
- 40% vs 15.8% NCT02033889
- 40.8% vs 16.2% NCT02630706
- 21.1% vs 10.7% NCT01986881
- 33.7% vs 19.1% NCT02033889
- 20% vs 16.5% NCT01986881
- 20.7% vs 10.7% NCT01986881
- 24.9% vs 18.2% NCT01986881
- 39.9% vs 17% NCT02036515
- 11.3% vs 12.1% NCT01986855
- 36.6% vs 30.6% NCT02033889
- 35.3% vs 15.8% NCT02033889
- 34.8% vs 30.6% NCT02033889
- 24.6% vs 19.1% NCT02033889
- 18.6% vs 16.5% NCT01986881
- 27.8% vs 25% NCT01986881
- 32.7% vs 12.8% NCT01986881
- 32.7% vs 13.7% NCT02036515
- 28.2% vs 13.1% NCT01958671
- 32.1% vs 17% NCT02036515
- 16.2% vs 12.1% NCT01986855
- 38.2% vs 16.2% NCT02630706
- 32.7% vs 25% NCT01986881
- 37% vs 12.8% NCT01986881
- 33.3% vs 13.7% NCT02036515
- 31.3% vs 8.3% NCT02226003
- 35.7% vs 8.3% NCT02226003
- 31.9% vs 32.8% NCT02099110
- 26.4% vs 32.8% NCT02099110
- 49.2% vs 32.8% NCT02099110
- 52.3% vs 32.8% NCT02099110
- 42.9% vs 15.6% NCT01059825
- 36.2% vs 15.6% NCT01059825
- 38.6% vs 15.6% NCT01059825
- 44% vs 15.6% NCT01059825
Fasting plasma glucose, change
- Empagliflozin
- -1.8 vs 0.3−2.1 vs placeboNCT01734785
11 other results
- -1.5 vs 0.3 NCT01734785
- -1.8 vs -1.8 NCT01719003
- -1.6 vs -1.8 NCT01719003
- -2.8 vs -1.8 NCT01719003
- -2.4 vs -1.8 NCT01719003
- -2.6 vs -1.8 NCT01719003
- -2.5 vs -1.8 NCT01719003
- -1.0 vs -0.0 NCT01649297
- -1.3 vs -0.0 NCT01649297
- -1.5 vs -0.0 NCT01649297
- -1.2 vs -0.0 NCT01649297
- Ertugliflozin
- -1.9 vs -0.9−1 vs placeboNCT01986881
63 other results
- -1.6 vs -0.5 NCT01986881
- -1.4 vs -0.2 NCT01986881
- -1.3 vs -0.2 NCT01986881
- -1.8 vs -0.9 NCT01986881
- -0.9 vs 0.2 NCT01986881
- -1.6 vs -0.5 NCT01986881
- -1.2 vs -0.2 NCT01986881
- -1.1 vs -0.2 NCT01986881
- -2.2 vs -0.1 NCT02033889
- -1.8 vs -0.4 NCT01986881
- -0.6 vs -0.3 NCT01986881
- -1.8 vs -0.1 NCT02036515
- -1.9 vs -0.7 NCT02033889
- -1.6 vs -0.6 NCT02033889
- -1.5 vs -0.1 NCT02033889
- -1.5 vs -0.4 NCT01986881
- -0.8 vs 0.2 NCT01986881
- -0.8 vs -0.3 NCT01986881
- -2.4 vs 0.0 NCT01958671
- -1.1 vs -0.3 NCT01986855
- -1.9 vs -0.4 NCT02630706
- -1.5 vs -0.8 NCT01986881
- -2.0 vs -0.3 NCT01986881
- -1.5 vs 0.2 NCT02036515
- -1.9 vs 0.0 NCT01958671
- -1.5 vs -0.1 NCT02036515
- -0.7 vs -0.3 NCT01986855
- -2.1 vs -0.4 NCT02630706
- -1.6 vs -0.8 NCT01986881
- -2.0 vs -0.3 NCT01986881
- -1.2 vs -0.7 NCT02033889
- -1.4 vs 0.2 NCT02036515
- -1.0 vs -0.6 NCT02033889
- -1.1 vs 0.5 NCT04029480
- -0.7 vs 1.2 NCT04029480
- -4.7 vs 0.8 NCT01986881
- -0.1 vs 0.8 NCT01986881
- -2.0 vs -1.4 NCT02099110
- -2.0 vs -1.4 NCT02099110
- -2.7 vs -1.4 NCT02099110
- -2.4 vs -1.4 NCT02099110
- -1.3 vs 0.1 NCT01059825
- -1.4 vs 0.2 NCT01059825
- -1.7 vs 0.2 NCT01096667
- -1.3 vs 0.3 NCT01059825
- -1.3 vs -0.3 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -1.6 vs 0.1 NCT01059825
- -1.7 vs 0.2 NCT01059825
- -1.7 vs 0.2 NCT01096667
- -1.5 vs 0.3 NCT01059825
- -1.8 vs -0.3 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -1.8 vs 0.1 NCT01059825
- -1.8 vs 0.2 NCT01059825
- -1.6 vs 0.3 NCT01059825
- -1.5 vs 0.3 NCT01059825
- -1.0 vs 0.1 NCT01059825
- -1.0 vs 0.2 NCT01059825
- -0.8 vs 0.2 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -0.6 vs -0.3 NCT01096667
- -0.8 vs 0.3 NCT01059825
3-point MACE (% with event)
- Empagliflozin
- 10.4% vs 12.1%−1.7 vs placeboNCT01131676
2 other results
- 10.5% vs 12.1% NCT01131676
- 10.5% vs 12.1% NCT01131676
- Ertugliflozin
- —Not posted · NCT03717194
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. Empagliflozin: 13 of 13 rows · Ertugliflozin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Empagliflozin Rows use multiple source trials | Ertugliflozin Rows use multiple source trials |
|---|---|---|
| Ambulatory DBP absolute change · mmHg | -6.38 vs -1.48 placebo mmHg @ 24wk10 mg-25 mga,b,c,d NCT02182830 · Phase 3 · registry result, not featured evidence | -2.34 vs 0.77 placebo mmHg @ 4wk5 mge,a,b,c,d NCT01096667 · Phase 2 · registry result, not featured evidence show 2 more doses-1.5 vs 0.77 placebo mmHg @ 4wk25 mg NCT01096667 · Phase 2 · registry result, not featured evidence -1.89 vs 0.77 placebo mmHg @ 4wk1 mg NCT01096667 · Phase 2 · registry result, not featured evidence |
| Ambulatory SBP absolute change · mmHg | -10.33 vs -1.94 placebo mmHg @ 24wk10 mg-25 mga,b,c,d NCT02182830 · Phase 3 · registry result, not featured evidence | -3.73 vs 0.26 placebo mmHg @ 4wk5 mge,a,b,c,d NCT01096667 · Phase 2 · registry result, not featured evidence show 2 more doses-3.42 vs 0.26 placebo mmHg @ 4wk25 mg NCT01096667 · Phase 2 · registry result, not featured evidence -2.71 vs 0.26 placebo mmHg @ 4wk1 mg NCT01096667 · Phase 2 · registry result, not featured evidence |
| DBP absolute change · mmHg | -3.37 vs -1.59 placebo mmHg @ 24wk10 mge,b,c,f NCT04233801 · Phase 3 · registry result, not featured evidence show 1 more dose-0.94 vs -1.59 placebo mmHg @ 24wk25 mg NCT04233801 · Phase 3 · registry result, not featured evidence | -0.97 vs 1.21 placebo mmHg @ 26wk15 mg + 100 mge,b,c,f NCT02226003 · Phase 3 · combination show 1 more dose-0.44 vs 1.21 placebo mmHg @ 26wk5 mg + 100 mg NCT02226003 · Phase 3 · combination |
| Fasting Plasma Glucose Change mg/dL absolute change · mg | -19.48 vs 15.7 placebo mg @ 26wk10 mg, 25 mge,g,h NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 show 1 more dose-18.45 vs 15.7 placebo mg @ 26wk10 mg, 25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 | -55.36 vs -9.3 placebo mg @ 26wk15 mg + 100 mge,g,h NCT02226003 · Phase 3 · combination show 1 more dose-48.25 vs -9.3 placebo mg @ 26wk5 mg + 100 mg NCT02226003 · Phase 3 · combination |
| GFR mL/Min 1 73m2 absolute value · mL | 124 vs 132.5 placebo mL @ 4wk25 mgi,c,j NCT02632747 · Phase 2 · registry result, not featured evidence | 48.6 vs 50.1 placebo mL @ 12wki,c,j NCT03416270 · Phase 2 · registry result, not featured evidence |
| HbA1c Less Than 6 5 responder rate · % of participants | 21.2% (n=52) vs 9.4% (n=53) placebo @ 26wk10 mg, 25 mge,g,c NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 show 1 more dose16.7% (n=6) vs 9.4% (n=53) placebo @ 26wk10 mg, 25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 | 12.2% (n=205) vs 2.9% (n=209) placebo @ 26wk15 mge,g,c NCT02033889 · Phase 3 show 1 more dose8.7% (n=207) vs 2.9% (n=209) placebo @ 26wk5 mg NCT02033889 · Phase 3 |
| SBP absolute change · mmHg | -5.56 vs -1.95 placebo mmHg @ 24wk10 mge,b,c,f NCT04233801 · Phase 3 · registry result, not featured evidence show 1 more dose-2.96 vs -1.95 placebo mmHg @ 24wk25 mg NCT04233801 · Phase 3 · registry result, not featured evidence | -3.98 vs 2.41 placebo mmHg @ 26wk15 mg + 100 mge,b,c,f NCT02226003 · Phase 3 · combination show 1 more dose-2.04 vs 2.41 placebo mmHg @ 26wk5 mg + 100 mg NCT02226003 · Phase 3 · combination |
| Seated DBP absolute change · mmHg | 0.78 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mge,k,h NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 show 1 more dose-3.2 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 | -1.1 vs -0.72 placebo mmHg @ 26wk15 mge,k,h NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 1 more dose-2.52 vs -0.72 placebo mmHg @ 26wk5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 |
| Seated SBP absolute change · mmHg | -0.12 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mge,k,h NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 show 1 more dose2.63 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 | -3.93 vs -2.22 placebo mmHg @ 26wk15 mge,k,h NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 1 more dose-5.54 vs -2.22 placebo mmHg @ 26wk5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 |
| Dropout rate | 23.7%10 mgl NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results23.2%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 8%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.7%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 8.7%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 8.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 15.9%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 —10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 6.2%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 11.2%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 4.4%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 9.4%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence 6.1%25 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25mg NCT02589626 · Phase 4 · registry result, not featured evidence 2.7%10 mg NCT04233801 · Phase 3 · registry result, not featured evidence 5.5%25 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 18.1%10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 7%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 10.2%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 7.5%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5.3%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 10%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 9.9%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 7.7%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT01947855 · Phase 3 · registry result, not featured evidence 0%25 mg NCT01947855 · Phase 3 · registry result, not featured evidence —Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 8.6%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 6%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 6.4%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 7.8%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence | —15 mgm NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results—15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.6%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15.8%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.2%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.2%15 mg NCT02033889 · Phase 3 9.7%5 mg NCT02033889 · Phase 3 22.9%15 mg NCT01999218 · Phase 3 24.3%5 mg NCT01999218 · Phase 3 12.5%15 mg NCT02099110 · Phase 3 9.6%5 mg NCT02099110 · Phase 3 11%15 mg + 100 mg NCT02099110 · Phase 3 · combination 9.1%5 mg + 100 mg NCT02099110 · Phase 3 · combination 7.7%15 mg NCT02036515 · Phase 3 —15 mg NCT02036515 · Phase 3 · combination 3.2%5 mg NCT02036515 · Phase 3 —5 mg NCT02036515 · Phase 3 · combination 1%15 mg + 100 mg NCT02226003 · Phase 3 · combination 2%5 mg + 100 mg NCT02226003 · Phase 3 · combination 9%15 mg NCT01986855 · Phase 3 8.2%5 mg NCT01986855 · Phase 3 —15 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 5.3%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 4.1%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence 0% NCT03416270 · Phase 2 · registry result, not featured evidence 5.3%5 mg NCT01096667 · Phase 2 · registry result, not featured evidence 7.7%25 mg NCT01096667 · Phase 2 · registry result, not featured evidence 5.1%1 mg NCT01096667 · Phase 2 · registry result, not featured evidence —5 mg NCT01059825 · Phase 2 · registry result, not featured evidence —25 mg NCT01059825 · Phase 2 · registry result, not featured evidence —10 mg NCT01059825 · Phase 2 · registry result, not featured evidence —1 mg NCT01059825 · Phase 2 · registry result, not featured evidence 39.3% NCT04167761 · Phase 1 · registry result, not featured evidence —15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence —1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 11.4%10 mgl NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results11.6%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 2.7%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.9%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 3.2%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.9%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.3%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 1.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 —10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 4.6%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 5.6%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 3.3%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 3.1%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence 3%25 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25mg NCT02589626 · Phase 4 · registry result, not featured evidence —10 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 1.7%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 2.4%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 0%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 3.5%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 2.9%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 2.3%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination —10 mg NCT01947855 · Phase 3 · registry result, not featured evidence —25 mg NCT01947855 · Phase 3 · registry result, not featured evidence —Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 5.9%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 1.8%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence | —15 mgm NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results—15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.7%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5%15 mg NCT02033889 · Phase 3 0.5%5 mg NCT02033889 · Phase 3 1.6%15 mg NCT01999218 · Phase 3 2%5 mg NCT01999218 · Phase 3 2%15 mg NCT02099110 · Phase 3 1.2%5 mg NCT02099110 · Phase 3 0.8%15 mg + 100 mg NCT02099110 · Phase 3 · combination 1.2%5 mg + 100 mg NCT02099110 · Phase 3 · combination 0.6%15 mg NCT02036515 · Phase 3 —15 mg NCT02036515 · Phase 3 · combination 0.6%5 mg NCT02036515 · Phase 3 —5 mg NCT02036515 · Phase 3 · combination —15 mg + 100 mg NCT02226003 · Phase 3 · combination —5 mg + 100 mg NCT02226003 · Phase 3 · combination 0%15 mg NCT01986855 · Phase 3 0.6%5 mg NCT01986855 · Phase 3 —15 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 0.6%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 1.2%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence — NCT03416270 · Phase 2 · registry result, not featured evidence —5 mg NCT01096667 · Phase 2 · registry result, not featured evidence —25 mg NCT01096667 · Phase 2 · registry result, not featured evidence —1 mg NCT01096667 · Phase 2 · registry result, not featured evidence —5 mg NCT01059825 · Phase 2 · registry result, not featured evidence —25 mg NCT01059825 · Phase 2 · registry result, not featured evidence —10 mg NCT01059825 · Phase 2 · registry result, not featured evidence —1 mg NCT01059825 · Phase 2 · registry result, not featured evidence — NCT04167761 · Phase 1 · registry result, not featured evidence —15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence —1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 37.4%10 mgl NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results39%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 4.9%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.2%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 0.5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.3%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 1.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 5.4%10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 0%25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 12.3%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 10.5%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 8.9%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 6.3%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25 mg NCT02589626 · Phase 4 · registry result, not featured evidence 3%25mg NCT02589626 · Phase 4 · registry result, not featured evidence 13.7%10 mg NCT04233801 · Phase 3 · registry result, not featured evidence 9.6%25 mg NCT04233801 · Phase 3 · registry result, not featured evidence 5.2%25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 0.9%10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 3.7%10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence 3.6%25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 4.5%10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 0.6%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 1.8%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 3.8%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.2%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 3.5%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.2%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT01947855 · Phase 3 · registry result, not featured evidence 0%25 mg NCT01947855 · Phase 3 · registry result, not featured evidence 6.4%Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence 7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 0%25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 2.3%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 0.9%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 3.2%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence | 7.3%15 mgm NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results7.1%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 34.1%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.9%15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.5%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 7%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 34.9%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.3%5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.9%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.1%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.8%15 mg NCT02033889 · Phase 3 9.7%5 mg NCT02033889 · Phase 3 7.4%15 mg NCT01999218 · Phase 3 9.2%5 mg NCT01999218 · Phase 3 2%15 mg NCT02099110 · Phase 3 4.8%5 mg NCT02099110 · Phase 3 4.9%15 mg + 100 mg NCT02099110 · Phase 3 · combination 3.7%5 mg + 100 mg NCT02099110 · Phase 3 · combination —15 mg NCT02036515 · Phase 3 2%15 mg NCT02036515 · Phase 3 · combination —5 mg NCT02036515 · Phase 3 8.3%5 mg NCT02036515 · Phase 3 · combination 3.1%15 mg + 100 mg NCT02226003 · Phase 3 · combination 2%5 mg + 100 mg NCT02226003 · Phase 3 · combination 19.4%15 mg NCT01986855 · Phase 3 16.5%5 mg NCT01986855 · Phase 3 3.8%15 mg NCT04029480 · Phase 3 · registry result, not featured evidence 3.2%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 0%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 4.5%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 5.9%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 5.3%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence 17.6% NCT03416270 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01096667 · Phase 2 · registry result, not featured evidence 0%25 mg NCT01096667 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01096667 · Phase 2 · registry result, not featured evidence 3.6%5 mg NCT01059825 · Phase 2 · registry result, not featured evidence 1.8%25 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0%10 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0% NCT04167761 · Phase 1 · registry result, not featured evidence 0%15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mgl hypoglycaemia 29.6% (placebo 29.4%) urinary tract infection 14.5% (placebo 14.7%) hyperglycaemia 9.3% (placebo 18.1%) NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 37 more results25 mg hypoglycaemia 28.7% (placebo 29.4%) urinary tract infection 14.4% (placebo 14.7%) nasopharyngitis 9.4% (placebo 9.3%) NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 10mg hypoglycaemia 15.6% (placebo 9.8%) urinary tract infection 9.4% (placebo 6.7%) nasopharyngitis 8% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 10mg nasopharyngitis 5.5% (placebo 4.9%) urinary tract infection 4.1% (placebo 6.7%) hyperglycaemia 2.3% (placebo 12.4%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 25mg hypoglycaemia 12.9% (placebo 9.8%) urinary tract infection 6.9% (placebo 6.7%) nasopharyngitis 6% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 25mg hypoglycaemia 8.9% (placebo 9.8%) hyperglycaemia 7.9% (placebo 12.4%) nasopharyngitis 5% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 25mg nasopharyngitis 7% (placebo 4.9%) upper respiratory tract infections 4.2% (placebo 5.3%) urinary tract infection 4.2% (placebo 6.7%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 25mg nasopharyngitis 7.2% (placebo 4.9%) urinary tract infection 7.2% (placebo 6.7%) diarrhoea 5.8% (placebo 0%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 10 mg headache 16.2% (placebo 15.5%) hypoglycaemia 16.2% (placebo 12.1%) vitamin d deficiency 13.5% (placebo 13.8%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 25 mg hypoglycaemia 17.2% (placebo 12.1%) blood ketone body increased 10.3% (placebo 3.4%) headache 10.3% (placebo 15.5%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 10 mg constipation 10.8% (placebo 4.7%) pyrexia 6.2% (placebo 4.7%) nasopharyngitis 4.6% (placebo 6.3%) NCT04531462 · Phase 4 · registry result, not featured evidence 10 mg nasopharyngitis 34.9% (placebo 31.1%) hypoglycaemia 27.9% (placebo 21.1%) pollakiuria 10.5% (placebo 2.2%) NCT02589639 · Phase 4 · registry result, not featured evidence 25 mg hypoglycaemia 27.8% (placebo 21.1%) nasopharyngitis 26.7% (placebo 31.1%) pollakiuria 10% (placebo 2.2%) NCT02589639 · Phase 4 · registry result, not featured evidence 10 mg viral upper respiratory tract infection 31.3% fall 3.1% influenza 0% NCT02589626 · Phase 4 · registry result, not featured evidence 25mg viral upper respiratory tract infection 33.3% influenza 9.1% fall 6.1% NCT02589626 · Phase 4 · registry result, not featured evidence 10 mg hypoglycaemia 20.5% (placebo 15.1%) urinary tract infection 8.2% (placebo 13.7%) hyperlipidaemia 5.5% (placebo 2.7%) NCT04233801 · Phase 3 · registry result, not featured evidence 25 mg hypoglycaemia 15.1% (placebo 15.1%) urinary tract infection 8.2% (placebo 13.7%) hyperlipidaemia 5.5% (placebo 2.7%) NCT04233801 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg viral upper respiratory tract infection 26.7% (placebo 22.2%) blood ketone body increased 13.8% (placebo 10.2%) back pain 6% (placebo 2.8%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg viral upper respiratory tract infection 15% (placebo 22.2%) back pain 2.8% (placebo 2.8%) contusion 2.8% (placebo 0.9%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg-25 mg lipase increased 7.5% (placebo 3.9%) cough 6.3% (placebo 1.3%) upper respiratory tract infection 2.5% (placebo 5.2%) NCT02182830 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg nasopharyngitis 3.6% (placebo 7.3%) lipase increased 2.7% (placebo 5.5%) urinary tract infection 2.7% (placebo 6.4%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg urinary tract infection 7.1% (placebo 6.4%) nasopharyngitis 4.5% (placebo 7.3%) lipase increased 3.6% (placebo 5.5%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg qd dyslipidaemia 8.7% urinary tract infection 7% upper respiratory tract infection 2.9% NCT01719003 · Phase 3 · registry result, not featured evidence 25 mg qd urinary tract infection 7.8% dyslipidaemia 6.6% upper respiratory tract infection 4.2% NCT01719003 · Phase 3 · registry result, not featured evidence 12.5 mg Bid + 1000 mg Bid diarrhoea 7.5% dizziness 5.7% gastritis 5.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 12.5 mg Bid + 1000 mg Bid urinary tract infection 10.6% diarrhoea 7.1% dyslipidaemia 4.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 12.5 mg Bid + 500 mg Bid urinary tract infection 10% dizziness 5.3% diarrhoea 3.5% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5 mg Bid + 1000 mg Bid urinary tract infection 7% dyslipidaemia 4.7% upper respiratory tract infection 4.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5 mg Bid + 500 mg Bid dyslipidaemia 8.9% diarrhoea 5.3% urinary tract infection 5.3% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 10 mg nasopharyngitis 10% (placebo 4.8%) anal inflammation 0% (placebo 0%) bartholinitis 0% (placebo 0%) NCT01947855 · Phase 3 · registry result, not featured evidence 25 mg anal inflammation 5.3% (placebo 0%) bartholinitis 5.3% (placebo 0%) pollakiuria 5.3% (placebo 0%) NCT01947855 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.1% glomerular filtration rate decreased 3.8% hyperkalaemia 3.8% NCT05254002 · Phase 2 · registry result, not featured evidence hyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination 25 mg ketosis 19.4% (placebo 3.3%) fatigue 9.7% (placebo 0%) headache 9.7% (placebo 10%) NCT02632747 · Phase 2 · registry result, not featured evidence 10 mg QD urinary tract infection 6.8% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 25 mg QD urinary tract infection 4.6% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 12.5 mg BID urinary tract infection 4.6% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 5 mg BID urinary tract infection 3.7% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence | 15 mgm hypoglycaemia 30.3% (placebo 31.4%) nasopharyngitis 3.5% (placebo 3.2%) upper respiratory tract infection 2.7% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 44 more results15 mg hypoglycaemia 16.8% (placebo 31.4%) nasopharyngitis 4.4% (placebo 3.2%) dizziness 3.5% (placebo 1.2%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg hypoglycaemia 31.1% (placebo 31.4%) urinary tract infection 9.5% (placebo 2%) nasopharyngitis 7.4% (placebo 3.2%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg hypoglycaemia 5.6% (placebo 31.4%) urinary tract infection 1.9% (placebo 2%) back pain 0% (placebo 0.6%) NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 29% (placebo 31.4%) dizziness 2.3% (placebo 1.2%) upper respiratory tract infection 2.3% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 13% (placebo 31.4%) hypertension 4% (placebo 0.6%) hyperglycaemia 3% (placebo 1.7%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 32.2% (placebo 31.4%) urinary tract infection 9.3% (placebo 2%) upper respiratory tract infection 7.2% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 5.5% (placebo 31.4%) back pain 3.6% (placebo 0.6%) hypertension 3.6% (placebo 0.6%) NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15 mg nasopharyngitis 7.2% (placebo 3.9%) upper respiratory tract infection 6.6% (placebo 5.9%) urinary tract infection 6.6% (placebo 12.4%) NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg urinary tract infection 8.3% (placebo 12.4%) vulvovaginal mycotic infection 7.7% (placebo 1.3%) constipation 7.1% (placebo 2.6%) NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg upper respiratory tract infection 10.2% (placebo 15.8%) back pain 9.8% (placebo 4.8%) hypoglycaemia 8.8% (placebo 20.6%) NCT02033889 · Phase 3 5 mg upper respiratory tract infection 11.1% (placebo 15.8%) headache 6.8% (placebo 4.8%) hypoglycaemia 6.8% (placebo 20.6%) NCT02033889 · Phase 3 5 mg upper respiratory tract infection 6.1% urinary tract infection 6.1% headache 5.6% NCT01999218 · Phase 3 15 mg + 100 mg hypoglycaemia 8.2% nasopharyngitis 4.9% urinary tract infection 3.3% NCT02099110 · Phase 3 · combination 5 mg + 100 mg urinary tract infection 5.8% nasopharyngitis 4.9% hypoglycaemia 3.7% NCT02099110 · Phase 3 · combination 15 mg nasopharyngitis 3.9% (placebo 3.3%) hypoglycaemia 3.3% (placebo 7.2%) urinary tract infection 3.3% (placebo 5.2%) NCT02036515 · Phase 3 · combination 5 mg back pain 5.1% (placebo 3.9%) nasopharyngitis 5.1% (placebo 3.3%) hypoglycaemia 4.5% (placebo 7.2%) NCT02036515 · Phase 3 · combination 15 mg + 100 mg urinary tract infection 2.1% (placebo 1%) hyperglycaemia 1% (placebo 6.2%) blood glucose increased 0% (placebo 7.2%) NCT02226003 · Phase 3 · combination 5 mg + 100 mg urinary tract infection 5.1% (placebo 1%) blood glucose increased 3.1% (placebo 7.2%) hyperglycaemia 0% (placebo 6.2%) NCT02226003 · Phase 3 · combination 15 mg hypoglycaemia 20.6% (placebo 29.2%) urinary tract infection 7.7% (placebo 9.7%) upper respiratory tract infection 7.1% (placebo 4.5%) NCT01986855 · Phase 3 5 mg hypoglycaemia 31% (placebo 29.2%) diarrhoea 6.3% (placebo 5.8%) cough 5.7% (placebo 1.3%) NCT01986855 · Phase 3 15 mg hypoglycaemia 19.2% (placebo 12.7%) nausea 15.4% (placebo 7.3%) vomiting 15.4% (placebo 5.5%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 14.3% (placebo 10.9%) hypoglycaemia 11.1% (placebo 12.7%) covid-19 7.9% (placebo 7.3%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg hypoglycaemia 11.5% (placebo 12.7%) nausea 7.7% (placebo 7.3%) vomiting 7.7% (placebo 5.5%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg nausea 13.6% (placebo 7.3%) abdominal pain 9.1% (placebo 5.5%) diarrhoea 9.1% (placebo 7.3%) NCT04029480 · Phase 3 · registry result, not featured evidence 15 mg hyperuricaemia 5.3% (placebo 12%) hypoglycaemia 5.3% (placebo 1.2%) nasopharyngitis 5.3% (placebo 6.6%) NCT02630706 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 5.3% (placebo 6.6%) hypoglycaemia 3.5% (placebo 1.2%) hyperuricaemia 2.9% (placebo 12%) NCT02630706 · Phase 3 · registry result, not featured evidence 5 mg genital infection fungal 7.9% (placebo 0%) athralgia 5.3% (placebo 0%) nasopharyngitis 5.3% (placebo 0%) NCT01096667 · Phase 2 · registry result, not featured evidence 25 mg fatigue 5.1% (placebo 0%) polyuria 5.1% (placebo 0%) dizziness 2.6% (placebo 5.3%) NCT01096667 · Phase 2 · registry result, not featured evidence 1 mg musculoskeletal pain 5.1% (placebo 0%) upper respiratory tract infection 2.6% (placebo 5.3%) urinary tract infection 2.6% (placebo 2.6%) NCT01096667 · Phase 2 · registry result, not featured evidence 5 mg arthralgia 10.9% (placebo 1.9%) headache 7.3% (placebo 3.7%) hypoglycaemia 5.5% (placebo 0%) NCT01059825 · Phase 2 · registry result, not featured evidence 25 mg genital infection fungal 7.3% (placebo 1.9%) diarrhoea 5.5% (placebo 1.9%) upper respiratory tract infection 5.5% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 10 mg urinary tract infection 9.1% (placebo 7.4%) genital infection fungal 5.5% (placebo 1.9%) upper respiratory tract infection 5.5% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 1 mg arthralgia 3.7% (placebo 1.9%) diarrhoea 3.7% (placebo 1.9%) upper respiratory tract infection 3.7% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 15 mg Oral + 100 ug Oral nasal congestion 12.5% back pain 0% headache 0% NCT02411929 · Phase 1 · registry result, not featured evidence · combination 15 mg Oral + 100 ug IV headache 25% back pain 12.5% nasal congestion 0% NCT02411929 · Phase 1 · registry result, not featured evidence · combination 15 mg decreased appetite 12.5% headache 12.5% tachycardia 12.5% NCT02115347 · Phase 1 · registry result, not featured evidence 15 mg arthralgia 12.5% back pain 12.5% dizziness 12.5% NCT02115347 · Phase 1 · registry result, not featured evidence 4 mg Once Daily diarrhoea 11.5% headache 7.7% abdominal pain 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 2 mg Once Daily headache 11.5% constipation 3.8% dizziness 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 2 mg Twice Daily abdominal pain 3.8% diarrhoea 3.8% dry mouth 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 1 mg Twice Daily headache 12% back pain 4% dyspepsia 4% NCT01054300 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 24 weeks versus 4 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fAssessment timepoints differ: 24 weeks versus 26 weeks.
- gPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
- hTreatment context differs: pooled versus combination.
- iPopulation context differs: registered conditions differ.
- jAssessment timepoints differ: 4 weeks versus 12 weeks.
- kPopulation context differs: age eligibility differs (includes children versus adolescents and adults); baseline_threshold differs (hba1c<=10.5, hba1c>=6.5 versus none recorded); comorbidity_diabetes differs (required versus none recorded); prior_therapy differs (none recorded versus unrestricted).
- lPopulation comparability has not been reviewed for 31 of these studies.
- mPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Empagliflozin
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 5 more results
+ 12 further endpoints in the CSV export.
Ertugliflozin
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 13 more results
show 13 more results
show 11 more results
show 1 more result
show 11 more results
show 1 more result
show 3 more results
show 3 more results
+ 18 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Empagliflozin's landscape · Ertugliflozin's landscape